The Salivary Gland Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Salivary Gland Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued products.

GlobalData tracks 55 drugs in development for Salivary Gland Cancer by 50 companies/universities/institutes. The top development phase for Salivary Gland Cancer is phase ii with 35 drugs in that stage. The Salivary Gland Cancer pipeline has 53 drugs in development by companies and two by universities/ institutes. Some of the companies in the Salivary Gland Cancer pipeline products market are: AstraZeneca, F. Hoffmann-La Roche and Johnson & Johnson.

The key targets in the Salivary Gland Cancer pipeline products market include Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).

The key mechanisms of action in the Salivary Gland Cancer pipeline product include Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2 with eight drugs in Phase II. The Salivary Gland Cancer pipeline products include 11 routes of administration with the top ROA being Intravenous and nine key molecule types in the Salivary Gland Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Salivary Gland Cancer overview

Salivary gland cancer refers to malignant tumors that develop in the tissues of the salivary glands, which produce saliva to aid in digestion and maintain oral health. These glands are located in various areas of the mouth and throat, including the parotid glands (the largest salivary glands), submandibular glands, sublingual glands, and numerous minor glands throughout the mouth. Salivary gland cancers can be classified into different types based on the specific cells they originate from, including mucoepidermoid carcinoma, adenoid cystic carcinoma, acinic cell carcinoma, and adenocarcinoma.

For a complete picture of Salivary Gland Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.